Videx Articles
UPJOHN ANTI-HIV AGENTS IN PHASE II TRIALS
5 April 1993
JANSSEN TO PRESS ON WITH R 89439 DEV'T
8 March 1993
TRIPLE THERAPY FOR HIV INFECTION
1 March 1993
HIVID AND VIDEX SHOW SIMILAR BENEFITS
1 February 1993
RELATIVE BENEFIT OF RETROVIR AND VIDEX
4 January 1993
CAN DIDANOSINE DOSE BE SLASHED?
14 December 1992
US RESULTS 3RD QTR
2 November 1992
EXPANDED ACCESS TO STAVUDINE
12 October 1992
SANYO-KOKUSAKU GOES INTO AIDS R&D
12 October 1992
FOCUS ON IVAX PRODUCT PIPELINE
12 October 1992
US APPROVES VIDEX FOR EXPANDED USE
5 October 1992
NEW DRUGS HIGHLIGHTED AT AIDS CONFERENCE
3 August 1992
ROCHE'S HIVID GETS APPROVAL IN USA
29 June 1992
JAPANESE DRUG APPROVALS
22 June 1992
FIRST EC LAUNCH OF DIDANOSINE
22 June 1992
VIDEX HEADING FOR JAPANESE APPROVAL
8 June 1992
US ACCELERATED APPROVAL VIEWED
4 May 1992
RETROVIR TO VIDEX SWITCH BENEFIT
4 May 1992
STRONG INCREASES IN 1991 AT BRISTOL-MYERS SQUIBB
20 April 1992
TRIAL COULD BOOST VIDEX ACCEPTANCE
20 April 1992
DRUG REVIEW PLAN SETS FOUR INITIATIVES
20 April 1992
VOLUME GROWTH FOR US DRUGMAKERS
9 March 1992
HIV POPULATIONS "ARE STABILIZING"
17 February 1992
NEW CHEMICAL ENTITIES UPDATE FOR 1991
10 February 1992
B-M SQUIBB GIVES HEART DRUGS FREE TO POOR
3 February 1992
B-MS' VIDEX FILED IN JAPAN
27 January 1992
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
